King

Antibiotic Lorabid (loracarbef) is acquired from Lilly for $90.5 mil. plus sales performance milestones bringing the total value of the deal to $158 mil. King plans to add at least 50 new sales reps to its 225-person force to help promote Lorabid along with Altace and other products. Lilly will continue to manufacture the product